Baxter Healthcare Corporation
95 Spring Street
New Providence, NJ 07974

Attention: Ivy Bautista
Associate Director, Global Regulatory Affairs

Dear Ms. Bautista:

Please refer to your supplemental new drug application dated July 31, 2009, received August 03, 2009, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Ethrane (enflurane, USP).

This “Changes Being Effected” supplemental new drug application provides for revisions to the **ADVERSE REACTIONS** section of the package insert.

We have completed our review of this application, and it is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed upon labeling text, which is identical to the content of labeling [21 CFR 314.50(l)(1)(i)] in structured product labeling (SPL) format submitted on July 31, 2009.

**CONTENT OF LABELING**

We note that your July 31, 2009, submission includes final printed labeling (FPL) for your package insert. We have not reviewed this FPL. You are responsible for assuring that the wording in this printed labeling is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

**LETTERS TO HEALTH CARE PROFESSIONALS**

If you issue a letter communicating important safety related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit an electronic copy of the letter to both this NDA and to the following address:

MedWatch
Food and Drug Administration
5600 Fishers Lane, Room 12B05
Rockville, MD 20857
REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Alison Meyer, Regulatory Project Manager, at (301) 796-1258.

Sincerely,

{See appended electronic signature page}

Bob A. Rappaport, M.D.
Director
Division of Anesthesia, Analgesia and Rheumatology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure: Package Insert
<table>
<thead>
<tr>
<th>Application Type/Number</th>
<th>Submission Type/Number</th>
<th>Submitter Name</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA-17087</td>
<td>SUPPL-48</td>
<td>BAXTER HEALTHCARE CORP</td>
<td>ETHRANE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ANESTHESIA CRITICAL CARE</td>
<td></td>
</tr>
</tbody>
</table>

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

BOB A RAPPAPORT
01/21/2010